Business
insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform
SOUTH SAN FRANCISCO, Calif., October 14, 2025--insitro, a pioneer in machine learning–driven drug discovery and development, and Bristol Myers Squibb (NYSE: BMY), today announced the next phase of their collaboration to discover new molecules with potential as new treatments for amyotrophic lateral sclerosis (ALS).
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1316,"height":383,"url":"https://media.zenfs.com/en/business-wire.com/c2a1f949f63f9141e19854573aab6789"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_ITIWcGxH9cKDBluX873sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c2a1f949f63f9141e19854573aab6789","width":960,"height":279},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/bDEyDP34hDFu0FIRWNHwCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02OTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c2a1f949f63f9141e19854573aab6789","width":1200,"height":349}},"lazy":false},{"type":"text","content":"Novel ALS target identified preclinically; next phase of collaboration will leverage insitro’s ChemML™ platform to discover molecules with potential as next-generation therapies for ALS","length":185,"tagName":"p","attribs":{}},{"type":"text","content":"insitro's ChemML™ platform integrates proprietary binding and ADMET data at scale with best-in-class machine learning and compute infrastructure to discover and optimize new small molecule therapeutics","length":205,"tagName":"p","attribs":{}},{"type":"text","content":"Collaboration extension builds on 5-year agreement announced in 2020","length":68,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., October 14, 2025--(BUSINESS WIRE)--insitro, a pioneer in machine learning–driven drug discovery and development, and Bristol Myers Squibb (NYSE: BMY), today announced the next phase of their collaboration to discover new molecules with potential as new treatments for amyotrophic lateral sclerosis (ALS).","length":333,"tagName":"p"},{"type":"text","content":"The collaboration extension will leverage insitro’s AI-enabled ChemML™ platform to design new medicines for a novel ALS target that was identified in the first biological evaluation phase and may provide up to $20 million in new funding for the one-year extension. The successful delivery of a new therapeutic from the collaboration could have an aggregate value of more than $2 billion in discovery, development, regulatory and commercial milestone payments to insitro in addition to royalty payments.","length":502,"tagName":"p"},{"type":"text","content":""Our colla...